Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936625 | 0.85 | CDC7 (0.54) | KDM4EGCGRMAPK14 | |
| SCHEMBL6936911 | 0.85 | CDC7 (0.54) | KDM4EGCGRMAPK14 | |
| SCHEMBL6932091 | 0.78 | MAPK14 (0.56) | KDM4EGCGRMAPK14 | |
| SCHEMBL6936901 | 0.78 | GCGR (0.67) | GCGRMAPK14 | |
| SCHEMBL6936591 | 0.78 | GCGR (0.52) | GCGRMAPK14 | |
| SCHEMBL6935654 | 0.76 | MAPK14 (0.45) | PIM1KDM4ECDK5CDK5R1GSK3B | |
| SCHEMBL6931288 | 0.76 | KDM4E (0.50) | KDM4ECDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL19946247 | 0.76 | SMN1; SMN2 (0.41) | PIM1KDM4EPTGER2PARP1MAPK14 | |
| SCHEMBL6934768 | 0.75 | MAPK14 (0.55) | GCGRMAPK14 | |
| SCHEMBL6937695 | 0.75 | MAPK14 (0.49) | KDM4ECDK5CDK5R1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | claimed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | claimed |
| CN-1328277-C | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | PIM1 916/4885KDM4E 2763/4885PTGER2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.